Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
12:52pm, Monday, 22'nd Dec 2025
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
Top large-cap gainers for Dec. 15-19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine funding news, and a major acquisition deal, with Rocket Lab, Affirm, and cru
BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Assenagon Asset Management S.A.
03:34am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 66.9% in the third quarter, according to its most recent filing with the Securities and Exc
Market Today: Oracle-TikTok JV, Tesla Pay Reinstated, Nike Sinks
05:35pm, Friday, 19'th Dec 2025
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play
12:41pm, Friday, 19'th Dec 2025
BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Amicus Therapeutics Inc. (FOLD) in a transaction valued at about $4.8 billion, a move that could stren
BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal
12:14pm, Friday, 19'th Dec 2025
BioMarin (BMRN) is acquiring Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash deal valued at approximately $4.8 billion. This acquisition, expecte
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
11:27am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
10:55am, Friday, 19'th Dec 2025
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
10:36am, Friday, 19'th Dec 2025
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal
09:03am, Friday, 19'th Dec 2025
BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
08:13am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
07:56am, Friday, 19'th Dec 2025
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Mi
AQR Capital Management LLC Acquires 2,654,768 Shares of BioMarin Pharmaceutical Inc. $BMRN
04:58am, Saturday, 13'th Dec 2025
AQR Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 90.7% during the undefined quarter, according to its most recent 13F filing with the SEC. The f
Critical Survey: BioMarin Pharmaceutical (NASDAQ:BMRN) & Contineum Therapeutics (NASDAQ:CTNM)
02:26am, Sunday, 30'th Nov 2025
BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Contineum Therapeutics (NASDAQ: CTNM - Get Free Report) are both medical companies, but which is the superior stock? We will compare the tw
